Nanobiotix to Present at H.C. Wainwright Investment Conference

Nanobiotix ( (NBTX) ) has shared an update.

On September 2, 2025, Nanobiotix announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 9, 2025, in New York. The company’s CEO, Laurent Levy, and CFO, Bart van Rhijn, will present at the event, which will be webcast live. This participation underscores Nanobiotix’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market visibility and investor relations.

The most recent analyst rating on (NBTX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company that focuses on pioneering nanoparticle-based therapeutic approaches to enhance treatment possibilities for patients with cancer and other major diseases. Founded in 2003 and headquartered in Paris, France, the company is listed on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix owns over 25 patent families related to nanotechnology platforms applicable in oncology, bioavailability and biodistribution, and central nervous system disorders.

Average Trading Volume: 10,173

Technical Sentiment Signal: Buy

Current Market Cap: $440.3M

Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.